皓宸医疗
(002622)
| 流通市值：35.45亿 | | | 总市值：35.45亿 |
| 流通股本：8.40亿 | | | 总股本：8.40亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 313,635,948.22 | 142,937,780.75 | 861,568,412.49 | 635,030,298.87 |
| 营业收入 | 313,635,948.22 | 142,937,780.75 | 861,568,412.49 | 635,030,298.87 |
| 二、营业总成本 | 353,745,281.85 | 167,162,234.16 | 856,749,904.93 | 630,093,894.86 |
| 营业成本 | 178,274,250.68 | 87,899,813.34 | 445,208,103.19 | 330,407,017.3 |
| 税金及附加 | 1,146,432.04 | 556,699.05 | 2,642,248.22 | 1,971,996.36 |
| 销售费用 | 76,940,756.43 | 32,459,362.47 | 186,112,607.74 | 141,873,589.24 |
| 管理费用 | 68,770,906.66 | 31,914,795.72 | 166,984,424.07 | 115,737,337.12 |
| 研发费用 | 7,966,580.46 | 4,192,860.44 | 10,114,606.53 | 5,583,042.65 |
| 财务费用 | 20,646,355.58 | 10,138,703.14 | 45,687,915.18 | 34,520,912.19 |
| 其中:利息费用 | 20,256,561.25 | 9,990,727.56 | 42,875,298.82 | 32,223,746.81 |
| 其中:利息收入 | 333,837.89 | 180,997.21 | 1,329,493.67 | 1,088,328.61 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 4,349,700.1 | 3,296,969.24 | -3,704,345.84 | 21,512,603.77 |
| 资产处置收益 | 678,017.94 | 25,778.45 | -576,307.24 | -1,486.97 |
| 资产减值损失(新) | - | -50 | - | -361,829.62 |
| 信用减值损失(新) | 2,596,096.74 | 1,539,438.55 | -2,030,381.08 | 1,016,271.72 |
| 其他收益 | 2,835,597.49 | 1,571,405.93 | 5,220,629.59 | 4,348,332.37 |
| 四、营业利润 | -29,649,921.36 | -17,790,911.24 | 3,728,102.99 | 31,450,295.28 |
| 加:营业外收入 | 129,009.74 | 127,384.61 | 2,394,058.19 | 186,579.91 |
| 减:营业外支出 | 2,550,185.05 | 185,352.04 | 15,409,196.37 | 334,261.26 |
| 五、利润总额 | -32,071,096.67 | -17,848,878.67 | -9,287,035.19 | 31,302,613.93 |
| 减:所得税费用 | 2,543,284.59 | 154,776.57 | 5,950,671.48 | 2,620,935.63 |
| 六、净利润 | -34,614,381.26 | -18,003,655.24 | -15,237,706.67 | 28,681,678.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -34,614,381.26 | -18,003,655.24 | -15,237,706.67 | 28,681,678.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -23,751,065.12 | -12,214,580.55 | -37,690,897.81 | 13,496,659.38 |
| 少数股东损益 | -10,863,316.14 | -5,789,074.69 | 22,453,191.14 | 15,185,018.92 |
| 扣除非经常损益后的净利润 | -23,558,534.57 | -12,546,173.49 | -23,883,257.61 | 12,991,517.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | -0.01 | -0.04 | 0.02 |
| (二)稀释每股收益 | -0.03 | -0.01 | -0.04 | 0.02 |
| 八、其他综合收益 | -1,502,531.57 | -3,764,533.94 | 2,942,040.89 | 1,540,094.91 |
| 归属于母公司股东的其他综合收益 | -1,502,531.57 | -3,764,533.94 | 2,942,040.89 | 1,540,094.91 |
| 九、综合收益总额 | -36,116,912.83 | -21,768,189.18 | -12,295,665.78 | 30,221,773.21 |
| 归属于母公司股东的综合收益总额 | -25,253,596.69 | -15,979,114.49 | -34,748,856.92 | 15,036,754.29 |
| 归属于少数股东的综合收益总额 | -10,863,316.14 | -5,789,074.69 | 22,453,191.14 | 15,185,018.92 |
| 公告日期 | 2025-08-29 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 带强调事项段的无保留意见 | |